Anti-BCOR / BCL-6 corepressor, clone BCOR/1311

0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced), 0.05% sodium azide. Bcl-6, a transcriptional repressor, can promote or inhibit apoptosis depending on the cell type and also plays an important role in normal immune responses. Bcl-6 negatively regulates NFkB expression, thereby inhibiting NFkB-mediated cellular functions and is frequently found to be deregulated in non-Hodgkin's lymphoma. BCoR (Bcl-6 corepressor) is a 1,755 amino acid protein that associates with histone deacetylases (HDACs) to transcriptionally repress Bcl-6. With ubiquitous expression, BCoR is localized to the nucleus where it interacts with other proteins through its three ANK repeat domains. Mutations in the gene encoding BCoR result in microphthalmia with associated anomalies 2, also known as anophthalmia, which is characterized by variable features, such as renal aplasia, mental retardation, hyospadias, microencephaly and cryptorchidism. There are four isoforms of BCoR which are produced as a result of alternative splicing events. Protein function: Transcriptional corepressor. May specifically inhibit gene expression when recruited to promoter regions by sequence-specific DNA- binding proteins such as BCL6 and MLLT3. This repression may be mediated at least in part by histone deacetylase activities which can associate with this corepressor. Involved in the repression of TFAP2A, impairs binding of BCL6 and KDM2B to TFAP2A promoter regions. Via repression of TFAP2A acts as a negative regulator of osteo-dentiogenic capacity in adult stem cells, the function implies inhibition of methylation on histone H3 'Lys-4' (H3K4me3) and 'Lys-36' (H3K36me2). [The UniProt Consortium]